Nature Sub-Journal: Oncolytic virus treatment of ovarian cancer has a promising future

Ovarian malignant tumor is one of the most common malignant tumors in female genital organs, and its incidence rate is second only to cervical cancer and uterine body cancer The most common ovarian cancer is epithelial cancer, followed by malignant germ cell tumor Among them, the death rate of epithelial ovarian cancer is the first in all kinds of gynecological tumors, which is a serious threat to women's lives The disease is typically asymptomatic in the early stage, usually leading to the emergence and diagnosis of late patients, with a 5-year survival rate of 46% Chemotherapy is the first choice of treatment, however, patients often have chemotherapy resistance Recently, researchers such as Hulin Curtis from Cardiff University, UK, designed and studied tumor targeting peptides for ovarian cancer Although the peptides found in this study have potential applications in targeted drug delivery, they need to be improved more effectively in the application of targeted viral therapy The study was published in nature, cancer gene therapy Oncolytic virus therapy based on human adenovirus (HAdV) vector has a significant hope for the treatment of advanced ovarian cancer Oncolytic virus invades tumor cells through cell surface molecules Therefore, one of the effective strategies of oncolytic virus therapy is to reconstruct a specific oncolytic virus, and then target those specific receptors overexpressed in tumor cells, and insert the virus into tumor cells It invades tumor cells and performs subsequent functions Human epidermal growth factor receptor-2 (HER-2) is such a specific receptor, which is over expressed in 1 / 4 of breast cancer and ovarian cancer patients The high expression of folate receptor α (FR α) in ovarian cancer cells provides an effective target for tumor selective antiviral therapy The clinical application of human adenovirus C5 is seriously hindered by the lack of tumor specificity, the interaction between existing antibodies and coagulation factors that isolate adenovirus to liver In order to improve the specificity of human adenovirus vector for ovarian cancer cells, researchers developed a group of recombinant vectors containing fr α, through gene binding from phage biological scanning recognition of peptide binding fr α Three phage peptides dwsswvyrdpqt, cignsntlc and ctvrtsaec were identified These three phage peptides have binding specificity to SKOV3 cells in vitro It is understood that this study is the first time to identify ctvrtsaec peptide, a similar peptide ctvrtsadc, which specifically targets prostate cancer cells in vivo by substituting glutamic acid for aspartic acid This study only proved that phage peptide can combine with fr α of SKOV3 cells in vitro, and it has the prospect of treating ovarian cancer In the context of relocating human adenovirus, due to the defect of intracellular transport, the identified peptide failed to enhance the fr α mediated SKOV3 cell transduction It is necessary to further study the reasons for the defects of human adenovirus vector transduction in fr α retargeting Reference source: doi.org/10.1038/s41417-019-0156-0 denigui statement: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.